Lv51
1130 积分 2021-12-10 加入
Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase 3 trial of toripalimab plus chemotherapy in advanced esophageal squamous cell carcinoma
6小时前
求助中
Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trial
14天前
已完结
Interval versus primary cytoreductive surgery in BRCA-mutated advanced-stage ovarian/peritoneal/tubal carcinoma
16天前
已关闭
Tisotumab vedotin in Japanese patients with recurrent or metastatic cervical cancer: results from the innovaTV 301/ENGOT-cx12/GOG-3057 trial
16天前
已关闭
Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone-receptor-positive HER2-negative breast cancer: final overall survival analysis of the phase 3 TROPION-Breast01 study
28天前
已完结
Capivasertib plus paclitaxel as first-line treatment for metastatic triple-negative breast cancer: Results from the randomised, global phase III CAPItello-290 trial
30天前
已完结
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy
1个月前
已完结
A phase 2 study of pembrolizumab and weekly paclitaxel for platinum-resistant epithelial ovarian cancer
1个月前
已关闭
Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer
1个月前
已关闭
Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib
1个月前
已关闭
皖公网安备34019202002308
